Consensus Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Market Closed - Nyse Other stock markets 01:40:00 21/05/2024 am IST			5-day change	1st Jan Change
0.37 ^USD	-0.19%		-1.10%	-13.97%

07/05	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Evolution of the average Target Price on Theriva Biologics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ad17992f3333d244e9c3a69b017.emlXvy4v_0ShFb_d9pXGcY-pGNYxT4Z8OX-12IWr5Yg.EBoc3EFKxg75eM-3r9GBMvfFQYZ6fuAzdBKDucObl7lMEx7Nd3WuKORg3A~298b5407cd774d84f4082dcf61f46dc9

Analyst Recommendations on Theriva Biologics, Inc.

Cantor Fitzgerald Initiates Coverage on Synthetic Biologics With Overweight Rating	20/22/20	MT
History shows stocks can weather rate hike cycle	16/22/16	RE
SYNTHETIC BIOLOGICS : Maxim Upgrades Synthetic Biologics to Buy From Hold; Price Target is $2.50	12/21/12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.37 USD

Average target price

2 USD

Spread / Average Target

+440.54%

High Price Target

2 USD

Spread / Highest target

+440.54%

Low Price Target

2 USD

Spread / Lowest Target

+440.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Theriva Biologics, Inc.

Cantor Fitzgerald
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar